SCLXW Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 birž. 2024 @ 23:00):
Our systems believe the stock currently is overvalued by -0.25% compare to its pairs and should correct downwards.

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid therapies for patients with acute and chronic pain...

Stats
Šios dienos apimtis	93 590
Vidutinė apimtis	0
Rinkos kapitalizacija	320.69M
EPS	$-0.240 ( Q1 \| 2024-05-13 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0 (Sector) 42.63 (Industry) 61.14
ATR14	$0.0210 (4.67%)

CRXT -31.16%

MIRA -2.00%

SCLX 7.82%

SCLXW 5.24%

Insider Trading

Date	Person	Action	Amount	type
2023-10-04	Ji Henry	Buy	200 000	Nonstatutory Stock Option (right to buy)
2023-10-04	Shah Jaisim	Buy	200 000	Nonstatutory Stock Option (right to buy)
2023-10-04	Wu Yue Alexander	Buy	250 000	Nonstatutory Stock Option (right to buy)
2023-10-04	Chun Jay	Buy	250 000	Nonstatutory Stock Option (right to buy)
2023-10-04	Ma Stephen Hoi	Buy	150 000	Nonstatutory Stock Option (right to buy)

INSIDER POWER
-88.45
Last 30 transactions
Buy: 13 352 730 \| Sell: 150 694 281

Koreliacija (AI algo v.1.1b): Overvalued: -0.25% $0.451 paired level. (Algoritmas realiuoju laiku stebi didžiausią koreliaciją turinčių akcijų pokyčius ir suteikia momentinę informaciją)

Tūris Koreliacija

Ilgas: -0.19 (neutral)

Trumpas: -0.55 (weak negative)

Signal:(52.69) Neutral

Scilex Holding Company Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Scilex Holding Company Koreliacija - Valiuta/Žaliavos

-0.24
( neutral )

-0.34
( neutral )

0.00
( neutral )

0.12
( neutral )

0.34
( neutral )

0.23
( neutral )

Scilex Holding Company Finansinės ataskaitos

Annual	2023
Pajamos:	$46.74M
Bruto pelnas:	$26.92M (57.58 %)
EPS:	$-0.880

FY	2023
Pajamos:	$46.74M
Bruto pelnas:	$26.92M (57.58 %)
EPS:	$-0.880

FY	2022
Pajamos:	$38.03M
Bruto pelnas:	$27.24M (71.61 %)
EPS:	$-0.170

Financial Reports:

No articles found.

Scilex Holding Company Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Scilex Holding Company

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid therapies for patients with acute and chronic pain. The company\'s principal product includes ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102 or SEMDEXA, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase 3 clinical trial to treat lumbosacral radicular pain; SP-103 for the treatment of low back pain, which is in Phase 2 clinical trails; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia that is in Phase 1 clinical trials. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.